IRON
8:30 AM
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 Launched Expanded Access Program (EAP) for bitopertin for eligible erythropoietic protoporphyria (EPP) patients
Presentation / Abstract • Phase 2discmedicine.com